Author(s)

Théodora M. Zohoncon^1,2,3,4, Joseph Sawadogo², Abdoul Karim Ouattara^1,5, Abdou Azaque Zoure^1,4,6, Marie N. L. Ouedraogo^1,4, Paul Ouedraogo^1,2,3, Florencia W. Djigma^1,3,4, Christelle W. M. Nadembèga^1,3,4, Raphael Kabore², Djénéba Ouermi^1,4, Dorcas Obiri-Yeboah^1,6, Jacques Simpore^1,2,3,4*

¹Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
²Faculty of Medicine, University Saint Thomas d’Aquin (USTA), Ouagadougou, Burkina Faso.
³Laboratoire de Biologie Moléculaire, Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, Burkina Faso.
⁴Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO, Ouaga, Burkina.
⁵Département de Biochimie microbiologie, Université Norbert Zongo/Centre Universitaire de Manga, Koudougou, Burkina Faso.
⁶Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.

Over the past three decades, genomic and epigenetic sciences have identified more than 70 genes involved in the molecular pathophysiology of Alzheimer’s disease (AD). DNA methylation, abnormal histone and chromatin regulation and the action of various miRNAs induce AD. The identification of mutated genes has paved the way for the development of diagnostic kits and the initiation of gene therapy trials. However, despite major advances in neuroscience research, there is yet no suitable treatment for AD. Therefore, the early diagnosis of this neurodegenerative disease raises several ethical questions, including the balance between the principle of non-maleficence and the principle of beneficence. The aims of this research were to present the genomic and ethical aspects of AD, and to highlight the ethical principles involved in its presymptomatic diagnosis and therapy. A systematic review of the literature in PubMed, Google Scholar and Science Direct was carried out to outline the genomic aspects and ethical principles relating not only to the presymptomatic diagnosis of AD, but also to its gene therapy. A total of 16 publications were selected. AD is a multifactorial disease that can be genetically classified into Sporadic Alzheimer’s Disease and Familial Alzheimer’s Disease based on family history. Gene therapy targeting specific disease-causing genes is a promising therapeutic strategy. Advancements in artificial intelligence applications may enable the prediction of AD onset several years in advance. While early diagnosis of AD may empower patients with full decision competence for early decision-making, it also carries implications for the patient’s family members, who are at risk of developing the disease, potentially becoming a source of confusion or anxiety. AD has a significant impact on the life of individuals at risk and their families. Given the absence of disease modifying therapy, genetic screening and early diagnosis for this condition raise ethical issues that must be carefully considered in the context of fundamental bioethical principles, including autonomy, beneficence, non-maleficence, and justice.

Neurodegenerative Diseases, Alzheimer’s Disease, Molecular Mechanism, Gene Therapy, Presymptomatic Diagnosis Ethics, Gene Therapy Ethics

Zohoncon, T. , Sawadogo, J. , Ouattara, A. , Zoure, A. , Ouedraogo, M. , Ouedraogo, P. , Djigma, F. , Nadembèga, C. , Kabore, R. , Ouermi, D. , Obiri-Yeboah, D. and Simpore, J. (2023) Presymptomatic Diagnosis and Gene Therapy for Alzheimer’s Disease: Genomic, Therapeutic, and Ethical Aspects—A Systematic Review. Advances in Alzheimer's Disease, 12, 55-74. doi: 10.4236/aad.2023.124005.